Clinical Trial Update: NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b and Phase 2 NAUTILUS trial evaluating OKI-179 plus binimetinib in NRAS-mutated melanoma and other RAS-pathway–altered solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Binimetinib (binimetinib)
• OKI-179

Snippet

Sponsor: OnKure, Inc. | Conditions: RAS Mutation, NRAS Gene Mutation | Phase 1, Phase 2 | Status: COMPLETED